| Autor: |
Thomsen W; Pediatric Hematology-Oncology, University of Utah and Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, UT., Maese L; Pediatric Hematology-Oncology, University of Utah and Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, UT.; University of Utah and Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, UT., Vagher J; University of Utah and Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, UT., Moore K; Department of Radiology, University of Utah and Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, UT., Cheshier SH; Department of Neurosurgery, University of Utah and Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, UT., Hofmann JW; Department of Neuropathology, University of California San Francisco, San Francisco, CA., Bruggers C; Pediatric Hematology-Oncology, University of Utah and Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, UT.; University of Utah and Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, UT. |
| Abstrakt: |
Competing Interests: Luke MaeseHonoraria: Jazz PharmaceuticalsConsulting or Advisory Role: Jazz Pharmaceuticals Jennie VagherConsulting or Advisory Role: InVitae Samuel H. CheshierPatents, Royalties, Other Intellectual Property: International Patent Application No. PCT/US2018/020905 Entitled: Treatment of Pediatric Brain Tumors with Targeting of CD47 Pathway. First Named Inventor: Sharareh Gholamin, Your Ref.: S17-082, Our Ref.: STAN-1400WO; US Application Serial No. 15/912,447 Entitled: Treatment of Pediatric Brain Tumors with Targeting of CD47 Pathway. First Named Inventor: Sharareh Gholamin, Your Ref.: S17-082, Our Ref.: STAN-1400; International Patent Application No. PCT/US2018/020905 Entitled: Treatment of Pediatric Brain Tumors with Targeting of CD47 Pathway. First Named Inventor: Sharareh Gholamin, Your Ref.: S17-082, Our Ref.: STAN-1400WO; US Application Serial No. 15/912,447 Entitled: Treatment of Pediatric Brain Tumors with Targeting of CD47 Pathway. First Named Inventor: Sharareh Gholamin, Your Ref.: S17-082, Our Ref.: STAN-1400No other potential conflicts of interest were reported. |
